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Signaling pathwaySporadically, patients with a proven defect in either mFAO or OXPHOS are described presentingwith ametabolic
proﬁle and clinical phenotype expressing concurrent defects in both pathways. Biochemical linkages between
both processes are tight. Therefore, it is striking that concurrent dysfunction of both systems occurs so infrequent.
In this review, the linkages between OXPHOS andmFAO and the hypothesized processes responsible for concur-
rent problems in both systems are reviewed, both from the point of viewof primary biochemical connections and
secondary cellular responses, i.e. signaling pathways constituting nutrient-sensing networks. We propose that
affected signaling pathways may play an important role in the phenomenon of concurrent defects. Recent data
indicate that interference in the affected signaling pathways may resolve the pathological phenotype even
though the primary enzyme deﬁciency persists. This offers new (unexpected) prospects for treatment of these
inborn errors of metabolism. This article is part of a Special Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Inborn errors of metabolism arise from single enzyme deﬁciencies
but behave as complex traits [1]. The broad spectrum of clinical presen-
tations that can be observed in patients with the same enzyme deﬁcien-
cy is a clear example of this. Apparently, cellular metabolism and
physiology have many ways to adapt to perturbations in biochemical
pathways, and each of these (mal)-adaptations comes with their own
set of clinical symptoms. Unbiased ‘-omics’ approaches i.e. transcripto-
mics and metabolomics, can be of great help to go beyond textbookoASH, Free CoA; CPT, Carnitine
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6.biochemistry and generate hypotheses concerning possible mecha-
nisms that account for these adaptations. Only recently application of
these approaches to the ﬁeld of inborn errors of metabolism has started
in the ﬁeld of mitochondrial diseases.
In the mitochondrion, mFAO, OXPHOS, and the tricarboxylic acid
(TCA) cycle function together in the formation of adenosine triphos-
phate (ATP). Mitochondrial FAO takes care of the repetitive shortening
of acyl-CoA esters for the generation of acetyl-CoA, NADH, and FADH2.
OXPHOS is the process of ATP synthesis via the transfer of electrons
from NADH and FADH2, which have been generated in mFAO or the
TCA cycle, to oxygen over the electron transport chain (ETC). According
to textbook biochemistry, this continuous regeneration of NAD+ and
FAD by the ETC and oxidation of the acetyl-residue of acetyl-CoA in
the Krebs cycle to release free CoA (CoASH) are essential for the mFAO
to proceed. It is inherent to this that dysfunctional OXPHOS should
accompany impairment of mFAO. However, the opposite is observed.
In humans, deﬁciencies in many of the enzymes important in mFAO
and OXPHOS have been described [2,3]. When defects and resulting
clinical symptoms are considered, mFAO and OXPHOS usually behave
as independently functioning systems (for reviews on individual
mFAO and OXPHOS defects and their respective clinical presentation
we refer to Table 1 and [3–8]). It is sporadically observed that patients
with an established OXPHOS or mFAO defect present with clinical
symptoms or metabolite patterns that imply concurrent defects in
both systems. The question then arises what molecular mechanisms
determine this sporadic occurrence of signs of a combined defect.
Fig. 1. General scheme of metabolic regulation. Legends: PTM: post-translational
modiﬁcation.
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the body to defects in mFAO and OXPHOS; the ‘primary biochemical
linkages’ and ‘secondary cellular response’. In Fig. 1 we depict several
levels of integration. At themetabolic level the conversion of substrates
into biomass, energy, andproducts takes place. At this level all biochem-
ical reactions take place, as well as the metabolite-driven regulation of
enzyme activity. Until now, the concurrence of mFAO and OXPHOS de-
fects has mainly been discussed at the level of ‘primary biochemical
linkages’, i.e. at this metabolic level. Indirectly, metabolism is regulated
via the other 3 levels, which are collectively considered the ‘secondary
cellular responses’. The second level represents the nutrient-sensing
signaling networks, which inﬂuence the biochemical reaction by
changing enzyme activities by post-translational modiﬁcation like
phosphorylation. The third level represents the level in which
nutrient-sensing transcription factors are active. Since these factors
are proteins themselves, they can also undergo post-translational mod-
iﬁcations. The reactions in the second and third level are driven by
changes in concentration of metabolites, i.e. AMP, NAD+, fatty acids or
phosphorylated sugars. The fourth level is the genome, in which tran-
scription of proteins feeds back on biochemically active enzymes, sig-
naling proteins and transcription factors.
In the next paragraphs, we will ﬁrst discuss the known primary
biochemical and structural linkages between OXPHOS and mFAO,
the reported clinical cases and related in vitro studies on the presen-
tation of concurrent OXPHOS and mFAO dysfunction. Next, we will
discuss the emerging literature on ‘secondary cellular responses’,
and their role in mitochondrial metabolism. Moreover, we will
suggest possible interventions in the pathological signaling as new
treatment options.2. Primary biochemical linkages between OXPHOS and mFAO
Biochemically, mFAO and OXPHOS are coupled by the TCA cycle,
complex I of the ETC and electron transfer ﬂavoprotein (ETF) (Fig. 2).
During each cycle of mFAO, one molecule of acetyl-CoA, one NADH,
and one FADH2 are formed. Acetyl-CoA enters the TCA cycle, generating
more NADH and FADH2, or is alternatively used for the production of
ketone bodies (KB) or lipogenesis. NADH donates its electrons directly
to complex I of the ETC. FADH2 is oxidized by transfer of electrons
to ETF. Reduced ETF subsequently transfers its electrons to ETF-
ubiquinone oxidoreductase (ETF-QO), which donates the electrons to
the ETC via ubiquinone (UQ) [9] (Fig. 2).Table 1
Clinical characteristics of OXPHOS and mFAO defects.
Adapted from ﬁg. 99-2 in [2], and [3].
OXPHOS defects
Metabolic proﬁle
Lactic acidemia, worsening upon glucose administration
Muscle
Muscle weakness, atrophy, hypotonia, myoglobinuria, hypertrophic cardiomyopathy
Gastro-intestinal
Pancreatic dysfunction, diabetes mellitus; renal failure and tubulopathy; diarrhea, villous atr
Hematology
Anemia, neutropenia, trombopenia, myelodysplasia
Nervous system
Hypotonia, cerebellar ataxia, leukodystrophy, hereditary spastic paraplegia, peripheral neuro
sensorineural deafness, optic/retinal atrophy, ptosis
Hormonal
Hypothyroidism, hypoparathyroidism, hypothalamic hypocorticism, GH deﬁciencyDuring electron transfer through the ETC, an electrochemical proton
gradient over the inner mitochondrial membrane is generated, and
subsequently dissipated while ATP is formed by complex V (Fig. 2) [2].
The formed ATP can be exported out of the mitochondria in exchange
for ADP by the adenine nucleotide transporter (ANT).
The mitochondrial NADH/NAD+ ratio is important for proper
functioning of mitochondrial metabolism, as the NAD+-linked 3-
hydroxyacyl-CoA dehydrogenases (HADHs: respectively short- and
long-chain 3-hydroxyacyl-CoA dehydrogenase, SCHAD and LCHAD)
are extremely sensitive to changes in the NADH/NAD+ ratio [10]. To a
lesser extent, NAD+ is required for functioning of the TCA cycle (isocitrate
dehydrogenase-3, α-ketoglutarate dehydrogenase complex, and malate
dehydrogenase), and pyruvate dehydrogenase complex (PDHc)
[3,11–13]. When an altered mitochondrial NADH/NAD+ ratio results
in an altered cytosolic NADH/NAD+ ratio, the lactate/pyruvate ratio
will change [2,11,14,15]. Furthermore, the FADH2/FAD ratio is impor-
tant for proper functioning of the group of ACADs inmFAO and complex
II in the TCA cycle and ETC [16].
Proteins involved in OXPHOS and mFAO are not only linked kineti-
cally viametabolite concentrations, but they also associate into physical
complexes. In humans, attachment of VLCAD to the inner mitochondrial
membrane enables a direct interaction betweenmFAO andOXPHOS [17,mFAO defects
(Hypo)ketotic hypoglycemia
Abnormal acylcarnitine proﬁle
Secondary free carnitine deﬁciency
Organic aciduria
Musculoskeletal or cardiac muscle weakness (VLCAD, LCHAD, MTP, SCAD)
ophy Hepatomegaly, fatty liver
HELLP syndrome in mothers carrying a fetus with LCHAD deﬁciency
pathy,
Fig. 2. Simpliﬁed version of the metabolic pathways that take place in the human mitochondrion. Legends: ANT: Adenine nucleotide transporter; CPT: Carnitine palmitoyltransferase;
CytC: cytochrome c; ETC: Electron transport chain; ETF: Electron transfer ﬂavoprotein; ETF-DH: ETF-dehydrogenase; FAD: Flavin adenine dinucleotide; mFAO: Mitochondrial fatty acid
oxidation; PDHc: Pyruvate dehydrogenase complex; TCA: Citric acid cycle; UQ: Ubiquinone.
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and has in pig liver been found to form a so-called “supercomplex”with
MCAD, ETF, UQ, and complex III [9]. Furthermore, “supercomplexes”
between complex I of the ETC and HADH, and complex I and VLCAD
were identiﬁed in pig heart mitochondria [20,21]. The acyl-CoA dehy-
drogenase (ACAD) proteins have also been found associated with
OXPHOS “supercomplexes”, in which various ETC complexes are assem-
bled in one large complex for presumably more efﬁcient electron trans-
port and limiting reactive oxygen species formation [9,22–25].
3. Defects in OXPHOS associated with secondary fatty acid
oxidation defects
The complex interrelationships between OXPHOS and mFAO have
been underlined in studies showing that defects in OXPHOS sporadically
lead to secondarymFAO inhibition.Most commonly, primary biochemical
links and altered ratios are put forward as an explanation for these obser-
vations [16,26–29]. We will present the reported clinical symptoms ac-
cording to the primary defect.
3.1. Complex I — NADH dehydrogenase defects
The clinical phenotype in patients with complex I deﬁciency is highly
variable (Table 1) [30]. Only a few patients have been reported with
signs of a combined complex I and secondary HADH dysfunction,
presenting with hepatosplenomegaly, cardiomyopathy, and muscle
weakness. Biochemically, lactic acidosis, increasing blood lactate afteran oral glucose bolus, and a low KB/FFA ratio corresponding to
hypoketosis during hypoglycemia have been reported [31]. Organic
acids in the urine showed elevated concentrations of lactate and 3-
hydroxydicarboxylic acids during hypoglycemia. LCHAD and SCHAD ac-
tivities were normal, whereas complex I activity measured in lympho-
blasts was severely lowered [27,29,32–34].
In vitro studies underlined these clinical ﬁndings, as oxidation of
labeled hexadecanoic acid (C16:0) was found to be decreased in cultured
skin ﬁbroblasts of a group of patients with a complex I deﬁciency when
tritium release of [9,10(n)-3H2]-C16:0wasmeasured [35,36]. Acylcarnitine
analysis in cultured skin ﬁbroblasts of two patients with identiﬁed
mtDNA mutations causing complex I deﬁciency showed multiple acyl-
CoAdehydrogenase deﬁciency (MADD)-like proﬁleswithmildly elevated
concentrations of C4-carnitine, and high concentrations of C6- and
C8-carnitine [37].3.2. Complex II — Succinate dehydrogenase defects
Two patients with a primary defect in complex II have been
described presenting with lactic acidosis, cardiomyopathy, hypotonia,
and hepatomegaly. In vitro [2H3]-C16:0 oxidation in cultured skin
ﬁbroblasts of these patients again led to elevated concentrations of
[2H3]-C4, -C6, -C8, -C10, and -C16 acylcarnitines, resembling acylcarnitine
proﬁles seen in MADD [16,37]. Selective SCAD and MCAD deﬁciency
were excluded. Besides lowered complex II activities, activities of com-
plexes III and IV were also mildly reduced [16].
Fig. 3. Schematic representation of proposed hypotheses on how OXPHOS affects mFAO. Legends: ACAD: Acyl-CoA dehydrogenase; ETF: electron transfer ﬂavoprotein;
HADH: Hydroxyacyl-CoA dehydrogenase; mFAO: mitochondrial fatty acid oxidation; UQ: ubiquinone.
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Only one patient with an isolated complex III deﬁciency has been
described presentingwith a hypoglycemia, lactic acidosis andmoderate
hepatomegaly after prolonged fastingwith gastro-enteritis [38]. The hy-
poglycemia respondedwell to glucose infusion. Upon a fasting tolerance
test again hypoglycemia and lactic acidosis developed. KB concentra-
tions and organic acid proﬁles were normal. FAO in cultured skin ﬁbro-
blasts was normal, and complex III deﬁciency was identiﬁed by enzyme
and mutation analysis [38].
In vitro studies in rat heart mitochondria acutely inhibited with
myxothiazol, an inhibitor of complex III, underlined the reported clinical
ﬁndings. Upon hexadecanoyl-CoA (C16:0-CoA) oxidation, titration with
myxothiazol led to accumulation ofmetabolites that typically accumulate
inHADHdysfunction. Direct effects ofmyxothiazol onMTP enzyme activ-
ity were excluded by enzyme assays. When the concentration of
myxothiazol was further increased above 0.2 μM, concentrations of the
abovementioned intermediates decreased and concentrations of C16-
CoA and -carnitine increased, indicating impaired ﬂux through VLCAD
[26,36]. That mild inhibition of complex III affects mFAO primarily
through HADH, ﬁts with the very low equilibrium constant of HADH,
which makes the mFAO more sensitive to the NADH/NAD+ than to the
FADH2/FAD ratio [39].3.4. Complex IV— Cytochrome c oxidase defects
Various clinical presentations indicating secondary mFAO inhibi-
tion resulting from complex IV deﬁciency have been described. Sim-
ilar to what has been described for complex I and III deﬁciencies, two
patients presented with a hypoglycemia. One of these patients pre-
sented with hypoglycemia, elevated lactate concentrations and
high KB concentrations already after a short-term fast (4 h). mFAO
was not studied in cultured skin ﬁbroblasts of this patient. In contrast,
the second patient presented with a hypoketotic hypoglycemia with de-
creased KB/FFA ratio, moderate hepatomegaly, and normal lactate levels
upon prolonged fasting (15 h), with normalmFAO in cultured skin ﬁbro-
blasts [38].
A combination of progressive neurological complaints, Reye-like syn-
dromewith convulsions, and abnormal organic aciduria (i.e. ethylmalonic
acid (EMA), glutaric acid, and N-acylglycine excretion, resembling
MADD), with normal [9,10(n)-3H2]-tetradecanoic acid oxidation in
cultured skin ﬁbroblasts has also been described in complex IV deﬁcient
patients [40,41].
In vitro studies in cultured skin ﬁbroblasts from patients with an iso-
lated complex IV deﬁciency underlined the reported clinical symptoms,
as C16:0-oxidation was loweredwhenmeasured by tritium release from
[9,10(n)-3H2]-C16:0 [36]. Acylcarnitine proﬁles in cultured skin ﬁbro-
blasts were MADD-like [37].Overall, MADD-like acylcarnitine proﬁles and hypoglycemia were
most commonly seen in patients with an OXPHOS defect and concur-
rent mFAO dysfunction (Fig. 3).
4. Defects in mFAO associated with secondary OXPHOS dysfunction
When considering the close biochemical interrelations in mitochon-
drial metabolism, primarymFAO defects may cause secondary dysfunc-
tional OXPHOS (Fig. 4). The experimental focus of most studies was on
the “intoxication” phenotype resulting from the accumulation of
mFAO intermediates, the severity of which largely depends on the
chain-length of the accumulating mFAO intermediates [42].
4.1. Long-chain mFAO defects
With regard to long-chain mFAO defects, only patients with isolated
LCHAD deﬁciency or with MTP deﬁciency have been described to
present clinically with symptoms such as lactic acidosis, retinopathy,
cardiomyopathy, muscle hypotonia, hepatosteatosis, and hypoglyce-
mia, combined with elevated plasma long-chain hydroxyacylcarnitines,
low free carnitine concentrations, and abnormal organic aciduria (with
elevated concentrations of C6–C10 dicarboxylic acids, and both saturated
and unsaturated adipic and suberic acids) [43–46]. One case report de-
scribed a patient who presented with unresponsiveness to intravenous
glucose during gastroenteritis with hypoglycemia, increasing lactate
concentrations and lactate/pyruvate ratio upon glucose administration,
and improvement upon administration of vitamins B1, C, K1, and riboﬂa-
vin. These symptoms are highly indicative for defective OXPHOS. In a
skeletal muscle biopsy enzyme activities of complexes I, II, III, and IV
were hardly detectable [43,45]. Similar ﬁndings were reported in post-
mortem studies in muscle tissue of LCHAD deﬁcient patients (all
homozygous for the G1528C mutation) [46].
When digitonin-permeabilized skin ﬁbroblasts from healthy
volunteers were incubated with C16:0-CoA and intermediates of
C16:0-CoA oxidation (hexadec-2-enoyl-CoA, 3-hydroxyhexadecanoyl-
CoA, 3-ketohexadecanoyl-CoA, and 3-hydroxytetradecanoic acid),
succinate- and glutamate-driven OXPHOS were inhibited in a
concentration-dependentmanner [47–51]. Decreased formation of ma-
late from succinate most likely resulted from direct inhibition of the
dicarboxylate carrier by C16:0-CoA or its β-oxidation intermediates
[48]. Additionally, ADP-induced respiration was found to be inhibited,
most likely due to direct inhibition of the mitochondrial adenine nucle-
otide transporter (ANT) by long-chain acyl-CoA esters [50,52].
Finally, in vitro studies showed uncoupling effects of the
long-chain mFAO fatty acids C16:0, 3-hydroxydodecanoic acid, 3-
hydroxytetradecanoic acid and 3-hydroxyhexadecanoic acid in rat
liver, brain and heart mitochondria [51,53,54]. In uncoupled mitochon-
dria, the proton gradient is not entirely used for ATP production, but
generates heat [55].
Fig. 4. Schematic representation of proposed hypotheses on how mFAO affects OXPHOS. Legends: ANT: Adenine nucleotide transporter; OXPHOS: oxidative phosphorylation; PDK:
pyruvate phosphate dikinase; PDHc: pyruvate dehydrogenase complex:⊣ Inhibition.
2025C.M.L. Touw et al. / Biochimica et Biophysica Acta 1842 (2014) 2021–20294.2. Medium-chain mFAO defects
Cases of MCAD deﬁciency leading to clinical presentations
corresponding to secondary OXPHOS defects have not been described
in literature, whereas in vitro studies showed various associations be-
tween accumulation of medium-chain mFAO intermediates and ham-
pered OXPHOS. These associations, however, were observed mostly at
non-physiological concentrations of these intermediates that are rarely
seen in patients with MCAD deﬁciency.
In vitro studies in homogenates of rat cerebral cortex revealed
an uncoupling effect of octanoic acid (OA), decanoic acid (DA), and cis-
4-decenoic acid (cDA) on mitochondrial function [56,57]. Only cDA
inhibited 2,6-dichloroindophenol reduction by succinate (complex II),
cytochrome c reduction by succinate (complex II + CoQ + complex III),
and oxidation of cytochrome c (complex IV) at concentrations that can
sporadically be found in plasma of MCAD deﬁcient patients during meta-
bolic crisis (0.1–0.25mM) [58]. However, synergism between these three
metabolites could not be excluded [58]. OA has further been described to
affect the intramitochondrial ATP/ADP ratio and lower the P/O ratio
(amount of ATP generated per reduced oxygen atom in OXPHOS) [59,
60]. In vitro studies in isolated bovine heart cells reported complex III in-
hibition by octanoyl-CoA in a concentration-dependent manner, possibly
due to the prevention of reduction of cytochrome b [61]. Octanoyl-CoA
was furthermore found to inhibit PDHc activity [61]. Octanoyl-carnitine,
which most commonly accumulates in blood of patients with MCAD de-
ﬁciency, did not exert these effects [59,61].4.3. Short-chain mFAO defects
As for MCAD deﬁciency, no case reports presenting patients with
SCAD deﬁciency and associated OXPHOS dysfunction have been
described in literature. However, it should be noted that the phenotyp-
ical spectrum varies considerably. Due to the position of SCAD inmFAO,whereMCAD can largely compensate for deﬁcient SCAD, it is difﬁcult to
understand the observed symptoms in these patients [3]. Consequently,
it is even questionable whether SCAD deﬁciency can be considered an
inborn error of metabolism. OXPHOS impairment by short-chain
mFAO intermediates had only been observed in vitro at concentrations
that were considerably higher than the concentrations that had been
observed in subjects with SCAD deﬁciency.
Subcutaneous injection of the main metabolite in SCAD deﬁcien-
cy, EMA (3 times 4 μmol/g body weight) in young rats did not affect
OXPHOS [62]. However, in vitro studies showed evidence for
inhibiting effects of short-chain mFAO intermediates. Incubation of
normal human muscle cells with EMA resulted in inhibition of cyto-
chrome c reduction by NADH (complex I + CoQ + complex III) at
concentrations of 0.25 mM [63]. Cytochrome c reduction by succi-
nate (complex II +CoQ + complex III) and 2,6-dichloroindophenol
reduction by succinate (complex II)were inhibited at higher concentra-
tions [64]. In rat livermitochondria, short-chain fatty acids have been re-
ported to decrease the P/O ratio in a concentration-dependent manner
upon incubation. However, the effect of butyratewasweaker than theef-
fect of medium-chain fatty acids at equal concentrations [60]. PDHc was
inhibited by acyl-CoA esters in a chain-length speciﬁc manner, with
short-chain monocarboxylic acyl-CoAs exerting the strongest effect.
This latter ﬁnding has a physiological explanation, as acetyl-CoA is a
product of PDHc,which allosterically inhibits PDHc and thereby prevents
overload of the TCA cycle. As for medium-chain length metabolites,
short-chain dicarboxylic acyl-CoAs or acylcarnitines were not found to
inhibit OXPHOS [28,61].
4.4. Multiple acyl-CoA dehydrogenase deﬁciency
Patients with MADD were deﬁned as patients with biochemical
characteristics of MADD due to the impairment of ETFα, ETFβ or ETF-
DH function. A subset of the patients carrying mutations in ETF-DH has
been described to have milder riboﬂavin-responsive forms of MADD [7].
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due to a riboﬂavin-transporter defect) with lowered activities of com-
plexes I and II of the ETC and secondary UQ deﬁciency [65–68]. Riboﬂavin
supplementation was found to induce complete recovery of the clinical
symptoms, with improved activities of the ACADs, and normalized activ-
ities of complexes I and II. Decreased availability of FAD was found to be
the main cause for the accompanying OXPHOS dysfunction in MADD
[65–67].
In summary, inhibition of ANT due to the accumulating intermedi-
ates, with secondary dicarboxylate carrier and PDHc dysfunction were
most commonly reported in studies on concurrent OXPHOS dysfunction
in response to an mFAO defect.
5. The role of secondary cellular responses
In general, clinical presentations of defects in OXPHOS or mFAO are
distinguishable separate entities. However, based on the close biochem-
ical interrelations, one would expect to regularly see clinical presenta-
tions of associations between OXPHOS and mFAO defects. As the
concurrence of OXPHOS andmFAO is sporadically displayed in a clinical
presentation, and the observed clinical presentations are very heteroge-
neous, these episodes cannot be solely explained by primary biochemi-
cal linkages.
We hypothesize that the enzyme insufﬁciencies or deﬁciencies that
were discussed in this reviewmay lead to improper activation of signal-
ing pathways due to alterations in metabolite concentrations, and
ultimately to an insurmountable obstacle causing failure to reach nor-
mal homeostasis. Even though a new steady state will eventually be
reached, it will be pathologic in nature. It should be realized that meta-
bolic functioning is tightly linked to metabolic regulation. Metabolic
diseases result in abnormal intracellular steady-state concentrations of
essential metabolites. Often normal oxygen uptake rates have been de-
scribed in patients withmitochondriopathies [69]. As a result, supply of
redox equivalents to reduce oxygen fromNADH and FADH2 via ETCwill
remain normal, as will the ﬂux through the TCA cycle. The partially
deﬁcient enzyme, however, can only work at normal speed if its re-
duced catalytic capacity is compensated by increased substrate and/or
decreased product concentrations. The cell will recognize the new
steady-state as a disrupted homeostasis and a counter-regulatory re-
sponsemay bemounted via signal transduction and/or gene expression.
We therefore hypothesize that these secondary cellular responses to
changes in the metabolome are an important, and currently under-
exposed, contributor to the development of a clinical phenotype.
Data underlining this hypothesis were recently presented in a study
on secondary cellular responses in tissue samples of patientswith a con-
ﬁrmed complex I deﬁciency. The data were not linked yet to mFAO im-
pairment. Zhang et al. studied the transcriptome bymicroarray analysis
in muscle biopsies and cultured skin ﬁbroblasts [69]. By means of this
unbiased approach a highly tissue-speciﬁc response was detected,
with alterations at the level of the global transcriptome and in parallel
in the activity of nutrient-sensing signaling networks of i.e. mTORC1,
AMPK, SIRT, FOXO and PPAR. Alterations in these networks resulted in
conﬂicting anabolic and catabolic responses occurring simultaneously.
Most strikingly, intervening in these secondary cellular responses by
treating complex I deﬁcient cultured skin ﬁbroblasts with nicotinic
acid, a precursor for NAD+, activated the NAD+-dependent protein
deacetylase SIRT, PPAR, mTORC1 and AMPK signaling. This led to
normalization of the activity of these networks, and improved cellular
respiratory capacity, without affecting the severity of the OXPHOS de-
fect. Similar effects were seen inmice with cardiac complex I deﬁciency
(due to knock-out of cardiacNdufs4) after treatment with nicotinamide
mononucleotide, another NAD+ precursor [70]. It should however be
noted that these effects may in part be due to alterations in the primary
biochemical reactions, because changes in NADH/NAD+ ratio will
directly affect metabolism as well. However, this possibility does not
apply to experiments performed by Johnson et al. in Ndufds4−/−mice,a mouse model for Leigh syndrome, a mitochondrial disease [71].
These mice suffer from a progressive neurodegenerative phenotype
characterized by lethargy, ataxia, weight loss, and ultimately death at
a median age of 50 days. When these mice were treated daily with
rapamycin, an inhibitor of the protein kinase complex mTORC1, the
symptoms alleviated dramatically, with a striking extension of median
and maximum lifespan (maximum 269 days). Apparently, normaliza-
tion of the nutrient-sensing networks caused the gene-expression
proﬁles to revert to what was observed in unaffected cells, despite
unaltered severity of the primary defect. Moreover, determination of
residual respiratory capacity in cultured skin ﬁbroblasts indicated that
a limiting respiratory capacity per se was not the main reason for the
secondary cellular responses [69,70].
Similarly, conﬂicting anabolic (i.e.mTORC1) and catabolic (i.e. AMP-
activated protein kinase) signaling was observed in studies in the
Twinkle mouse, which suffers from multiple mtDNA deletions. These
mtDNA lesions induced OXPHOS defects and late-onset mitochondrial
myopathy. Tyynismaa et al. determined a starvation-like response to
the OXPHOS defects, with induced Akt signaling and ﬁbroblast growth
factor 21 expression, a hormone related to fasting. Muscle protein deg-
radation was upregulated, and lipid synthesis was enhanced in this
mouse model [72]. When these mice were treated with a ketogenic or
high-fat diet, mitochondrial biogenesis was induced and ﬁbroblast
growth factor 21 expression normalized,without affectingmtDNAdele-
tion load. Collectively, these data clearly show that the clinical pheno-
type is not linked to the enzyme deﬁciency per se but results from
aberrant responses in signaling networks.
With regard to primary mFAO defects, altered mTORC1 signaling
was found to determine phenotype severity in zebraﬁsh with MADD
due to inactivation of the etfa gene, coding for ETFα protein. Etfa
deﬁcient zebraﬁsh showed similarities with MADD-patients both
biochemically and clinically. Acylcarnitine proﬁles were abnormal, and
fatty liver was observed. Additionally, hyperplastic neural progenitor
cells, hepatocytes and kidney tubule cells were observed. Increased
mTORC1 signaling was observed with cellular enlargement and prolif-
eration, which was abolished by rapamycin [73]. The authors speculate
that the persistent increase of leucine, activator of mTORC1 and sub-
strate of isovaleryl-CoA dehydrogenase, which needs ETFα for its activ-
ity, might be central in eliciting the secondary cellular response in
MADD [73].
Circumstantial evidence on a potential role for secondary cellular
responses in determining the clinical phenotype in mFAO defects was
also found in LCAD-deﬁcient mice [74]. In this mouse model, amino
acidmetabolismwas intrinsically disturbed, possibly also due to altered
mTORC activation resulting from the mFAO dysfunction.
In OXPHOS and mFAO defects, dietary treatment forms the basis of
therapy. Administration of high doses of intravenous glucose is neces-
sary in patients with a defect in mFAO who are in a metabolic crisis,
whereas this treatmentmay lead to an undesired increased lactate con-
centration and aggravation of symptoms in patients with an OXPHOS
defect. Patients with an OXPHOS defect, in particular complex I defects,
require a high lipid, low-carbohydrate diet supplementedwith vitamins
(e.g. riboﬂavin). Glucose oxidation largely occurs aerobically in the liver
and requires NAD+. As the NADH/NAD+ ratio is disturbed due to the
OXPHOS defect, glucose oxidation will provide more substrate for lac-
tate formation, and can thereby lead to further increased lactate concen-
trations in patients [2]. Vitamin supplementation is used as a treatment
to increase mitochondrial supply of FADH2 as compensation for the
diminished mitochondrial oxidation of NADH [2,8,43,75]. It should
however be realized that all of the traditional treatment modalities are
based on interfering in the primary biochemical reactions, generating
product but preventing excessive metabolite accumulation. It remains
to be determined if the negative effects of glucose supply in case of
OXPHOS defects truly result from the enzymatic defect, or whether
they result from aberrant signaling through nutrient sensing networks.
The recently published studies on the role of secondary cellular
2027C.M.L. Touw et al. / Biochimica et Biophysica Acta 1842 (2014) 2021–2029responses [69–72] point to new and exciting treatmentmodalities in re-
lation tomitochondriopathies [76]. Restoration of the secondary cellular
responsemay not only be able to prevent the clinical phenotype, but can
possibly also normalize the primary biochemical reactions. Various ex-
amples of NAD+ precursors (i.e. niacin and nicotinamide) have already
been approved by theU.S. Food andDrugAdministration andmaybe in-
teresting compounds to be studied in relation to at least OXPHOS de-
fects, but possibly also mFAO defects.
6. Conclusion and future perspectives
In this review we addressed the question why defects in OXPHOS
only sporadically behave as mFAO defects and vice versa. Inborn errors
ofmetabolismare complex traits [1]. The sporadic nature of clinical phe-
notypes displaying the concurrence of OXPHOS and mFAO defects is an
illustration of this principle. In this review, we discussed the published
reports on clinical presentations associated with combined defects in
both OXPHOS and mFAO. Based on the discussed results we can con-
clude, albeit preliminary, that instead of the primary biochemical
links, secondary cellular responses may well be the criterion to deter-
mine whether an individual will be at-risk for a metabolic crisis involv-
ing both OXPHOS andmFAO. Since nutrient-sensing signaling networks
integrate signals frommany sources, outside and inside the cell by com-
plex feed-forward and feed-backward responses, changes in the meta-
bolic state of affected cells or conditions in the environment of these
cells may well explain the accidental nature of these metabolic crises.
This problem asks for studies from a cellular point of viewwith an unbi-
ased approach i.e. an -omics approach (entailing respectively, metabo-
lomics, proteomics, and genomics at the level of the secondary
signaling pathways) and careful histology [77]. From the point of view
of OXPHOS defects, application of these unbiased approaches has result-
ed in identiﬁcation of new inborn errors of phospholipid metabolism
affecting OXPHOS [see [78] for a review]. Exome sequencing followed
by Sanger sequencing identiﬁed mutations in the gene coding for an
enzyme involved in phospholipid remodeling (SERAC1),which resulted
in OXPHOS defects [79]. Integrative analysis of the results of various -
omics technologies will be the next step. Although not yet applied in
clinical practice, combinations of metabolomics and genomics have
been used in studies of population cohorts with promising results
[80,81]. What is however missing are ‘phenomes’: thorough, coherent
and exact descriptions of patient clinical characteristics [82,83]. The
availability of structured phenotypic information in genomic databases
will improve clinical care [84].
In conclusion, the study of secondary cellular responses that result
from primary OXPHOS defects has now started. Most strikingly, these
studies hold promise to genuinely new approaches for diagnosing and
treating patients with OXPHOS and mFAO defects. It calls for the more
integrative approach of systemsmedicinewith implementation ofmed-
ical practice driven by clinical investigations, -omics technologies and
computational models.
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